<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042674</url>
  </required_header>
  <id_info>
    <org_study_id>NIS174-003</org_study_id>
    <nct_id>NCT05042674</nct_id>
  </id_info>
  <brief_title>Clinical Study on Rapid Antioxidant Protection and Immune Modulating Effects.</brief_title>
  <official_title>Clinical Study on Rapid Antioxidant Protection and Immune Modulating Effects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Natural Immune Systems Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Natural Immune Systems Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A trial on acute antioxidant protection and immune effects when 24 people consume a novel&#xD;
      nutraceutical blend compared to a placebo on different test days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, cross-over study design will be used to evaluate immune effects of consumption&#xD;
      of 25 mg ergothioneine. On the first clinic day, participants will take a placebo with a one&#xD;
      week wash out. Following the wash out week, participants will take 25 mg ergothioneine for 7&#xD;
      consecutive days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2021</start_date>
  <completion_date type="Anticipated">May 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in level of reduced glutathione</measure>
    <time_frame>2 hours</time_frame>
    <description>Mean fluorescence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mitochondrial mass and mitochondrial potential from baseline</measure>
    <time_frame>2 hours</time_frame>
    <description>Mean fluorescence</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in level of reduced glutathione</measure>
    <time_frame>1 week</time_frame>
    <description>Mean fluorescence</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in mitochondrial mass and mitochondrial potential from baseline</measure>
    <time_frame>1 week</time_frame>
    <description>Mean fluorescence</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Placebo, Ergothioneine 25mg, Ergothioneine 25mg for 1 week daily</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will consume placebo on first study day, consume 25mg of ergothioneine on second study day, then consume 25mg of ergothioneine daily for 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>after a blood draw placebo will be consumed followed by 2 additional blood draws</description>
    <arm_group_label>Placebo, Ergothioneine 25mg, Ergothioneine 25mg for 1 week daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ergothioneine, 25 miligrams</intervention_name>
    <description>after a blood draw 25 miligrams of ergothioneine will be consumed followed be 2 additional blood draws</description>
    <arm_group_label>Placebo, Ergothioneine 25mg, Ergothioneine 25mg for 1 week daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ergothioneine, 25 miligrams, daily for 1 week</intervention_name>
    <description>a blood draw will be administered after a week of consuming 25mg ergothioneine daily</description>
    <arm_group_label>Placebo, Ergothioneine 25mg, Ergothioneine 25mg for 1 week daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to comply with a 24-hour wash-out period for vitamins and nutritional&#xD;
             supplements&#xD;
&#xD;
          -  Willing to maintain a consistent diet and lifestyle routine throughout the study&#xD;
&#xD;
          -  Willing to avoid consumption of meals where the predominant ingredients include&#xD;
             mushrooms, seafood, and organ meat (liver, heart).*&#xD;
&#xD;
          -  Willing to abstaining from exercising on the morning of a study visit&#xD;
&#xD;
          -  Willing to abstain from use of coffee, tea, and soft drinks for at least one hour&#xD;
             prior to a clinic visit&#xD;
&#xD;
          -  Willing to abstain from music, candy, gum, computer/cell phone use, during clinic&#xD;
             visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous major gastrointestinal surgery&#xD;
&#xD;
          -  Active chronic immunological disease&#xD;
&#xD;
          -  Currently taking daily OTC medications, prescription pain medications, antipsychotic&#xD;
             medications, anti-inflammatory nutritional supplements judged by the study coordinator&#xD;
             to negate or camouflage the effects if the test product, nutritional supplements&#xD;
             containing medicinal mushroom extracts&#xD;
&#xD;
          -  Diagnose with Type I diabetes, autoimmune disorders&#xD;
&#xD;
          -  Getting regular joint injections&#xD;
&#xD;
          -  Active severe chronic disease (such as HIV, chronic hepatitis)&#xD;
&#xD;
          -  Currently experiencing intense stressful events/ life changes&#xD;
&#xD;
          -  Currently in intensive athletic training&#xD;
&#xD;
          -  Experiencing an unusual sleep routine&#xD;
&#xD;
          -  Unwilling to maintain a constant intake of supplements over the duration of the study&#xD;
&#xD;
          -  Anxiety about having blood drawn&#xD;
&#xD;
          -  Women who are pregnant, nursing, or trying to become pregnant&#xD;
&#xD;
          -  Known food allergies to ingredients in test product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gitte Jensen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIS Labs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gitte Jensen, PhD</last_name>
    <phone>541-884-0112</phone>
    <email>gitte@nislabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NIS Labs</name>
      <address>
        <city>Klamath Falls</city>
        <state>Oregon</state>
        <zip>97601</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Gitte Jensen, PhD</last_name>
      <phone>541-884-0112</phone>
      <email>gitte@nislabs.com</email>
    </contact>
    <investigator>
      <last_name>Gitte S Jensen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 4, 2021</study_first_submitted>
  <study_first_submitted_qc>September 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 11, 2021</last_update_submitted>
  <last_update_submitted_qc>September 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Natural Immune Systems Inc</investigator_affiliation>
    <investigator_full_name>Gitte Jensen, Ph.D.</investigator_full_name>
    <investigator_title>Research Director</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ergothioneine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

